Pentosan Polysulfate Sodium

Verify with FDA CVM →

152 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
152
Total Reports
2
Deaths Reported
130.0%
Death Rate

Active Ingredients

Pentosan Polysulfate Sodium

Administration Routes

IntramuscularUnknownIntra-ArticularSubcutaneousOther

Species Affected

Horse 144
Dog 7
Unknown 1

Most Affected Breeds

Quarter Horse 44
Horse (unknown) 20
Warmblood - Dutch 17
Thoroughbred 15
Horse (other) 9
Morgan 5
Hanovarian 5
Arab 4
Appaloosa 3
Selle Français 3

Most Reported Reactions

Injection site swelling 54
Hives (see also Skin) 19
Injection site pain 18
Injection site hair change 18
Lethargy (see also Central nervous system depression in Neurological) 10
Reluctant to move 9
Colic 8
Injection site reaction NOS 8
Injection site tenderness 7
Muscle stiffness 7
Not eating 6
Injection site lump 6

Outcome Breakdown

Recovered/Normal
74 (48.1%)
Outcome Unknown
66 (42.9%)
Ongoing
9 (5.8%)
Recovered with Sequela
3 (1.9%)
Died
2 (1.3%)

Data Summary

Metric Value
Total adverse event reports 152
Reports involving death 2
Case-fatality rate (reported events) 130.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Pentosan Polysulfate Sodium Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 152 adverse event reports referencing Pentosan Polysulfate Sodium, including 2 reports in which the animal died — a 130.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Pentosan Polysulfate Sodium. Reported administration routes include Intramuscular, Unknown, Intra-Articular, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Pentosan Polysulfate Sodium reports are Horse (144 reports), Dog (7 reports), Unknown (1 reports), with Horse accounting for the largest share. Within those species, Quarter Horse (44), Horse (unknown) (20), Warmblood - Dutch (17) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Pentosan Polysulfate Sodium are Injection site swelling (54), Hives (see also Skin) (19), Injection site pain (18), Injection site hair change (18). Of the 154 reports with a coded outcome, Recovered/Normal is the leading category at 48.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Pentosan Polysulfate Sodium.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial